GET THE APP

In-vivo angiogenesis in myocardial tissue engineering and regener | 50933
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

+44 1300 500008

In-vivo angiogenesis in myocardial tissue engineering and regeneration


International Conference & Exhibition on Clinical Research Dermatology, Ophthalmology & Cardiology

5-6 July 2011 San Francisco, USA

Lucian Lozonschi

Scientific Tracks Abstracts: JCEC

Abstract :

Myocardial infarction leads to myocardial ischemia, loss of vascularization and fibrosis. To regain function, new myocardium must replace the damaged tissue. Tissue engineering and stem cell co-transplantation proved to be promising novel therapies to achieve this goal, yet further understanding of these therapies is to be acquired. A major barrier to cell survival after delivery into the scar tissues involves proper vascularization. Our group uses the mouse dorsal skin fold chamber model to support the ectopic engraftment of neonatal mouse heart tissue as well as that of neonatal myocardial cell implants. The chambers are observed daily under bright field microscope and at predetermined intervals using fluorescent markers. We perfected a technique to obtain 100% engraftment rate. Angiogenesis occurs in both atrial and ventricular tissues as well as neonatal myocardial cells implants. Functional ectopic myocardial tissue was obtained after implantation of both atrial and ventricular neonatal myocardium. The spontaneous contractions in myocardial implants were observed using the intravital microscope and were confirmed by direct ultrasound examination. The beating rate was comparable to the mouse resting heart rate. This model can facilitate understanding and modulation of myocardial tissue engineering and regeneration.

Biography :

Myocardial infarction leads to myocardial ischemia, loss of vascularization and fi brosis. To regain function, new myocardium must replace the damaged tissue. Tissue engineering and stem cell co-transplantation proved to be promising novel therapies to achieve this goal , yet further understanding of these therapies is to be acquired. A major barrier to cell survival after delivery into the scar tissues invol ves proper vascularization. Our group uses the mouse dorsal skin fold chamber model to support the ectopic engraftment of neonatal mouse heart tissue as we ll as that of neonatal myocardial cell implants. The chambers are observed daily under bright fi eld microscope and at predetermined intervals using fl uorescent markers. We perfected a technique to obtain 100% engraftment rate. Angiogenesis occurs in both atrial and ventricular tissues a s well as neonatal myocardial cells implants. Functional ectopic myocardial tissue was obtained after implantation of both atrial and ventricular neonatal myocardium. The spontaneous contractions in myocardial implants were observed using the intravital microscope and were con fi rmed by direct ultrasound examination. The beating rate was comparable to the mouse resting heart rate. This model can facilitate understanding and modul ation of myocardial tissue engineering and regeneration

Top